Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Cardiomyopathy | Research article

A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count- to- HDL cholesterol ratio

Authors: Firdevs Aysenur Ekizler, Serkan Cay

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening complication of pregnancy. There is limited data regarding the predictors of persistent left ventricular (LV) systolic dysfunction. Recently, monocyte-to-high density lipoprotein (HDL) cholesterol ratio (MHR) has emerged as a novel indicator of inflammation and oxidative stress. We aimed to assess the predictive value of MHR on LV recovery in patients with PPCM.

Methods

A total of 64 patients with PPCM who admitted to our tertiary reference hospital between 2009 and 2017 were retrospectively analyzed in this study. Demographic and clinical data, laboratory parameters and echocardiographic findings were recorded. The duration of follow-up was at least 12 months after diagnosis for all participants. Recovery of LV systolic function was defined as the presence of LV ejection fraction (LV EF) > 45%. Univariate analysis was used to determine the significant predictors of persistent LV systolic dysfunction (non-recovery). A receiver operating characteristic (ROC) curve was used to establish the cut-off values for predictors.

Results

The mean follow-up duration was 72.1 ± 5.5 months. Of the 64 patients, 35 (55%) had persistent LVSD at their last follow-up while 29 (45%) showed LV EF improvement. The baseline MHR levels were significantly higher in the non-recovery group (P < 0.001). In univariate analysis, increased MHR levels (odds ratio:1.17; 95% confidence interval, 1.01–1.35; P < 0.001) significantly predicted LV non-recovery. Using a cut-off level of 9.73, MHR predicted persistent LV systolic dysfunction with a sensitivity of 89% and specificity of 79%. Besides, lower baseline LVEF increased WBC and CRP levels were identified as predictors of LV non-recovery.

Conclusions

Our data firstly indicated that elevated MHR was a significant predictor of persistent LV systolic dysfunction in PPCM. The MHR might contribute to determining high-risk patients with PPCM.
Literature
1.
go back to reference Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659–70.PubMedCrossRef Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659–70.PubMedCrossRef
2.
go back to reference Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the heart failure Association of the European Society of cardiology working group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–78.PubMedCrossRef Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the heart failure Association of the European Society of cardiology working group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–78.PubMedCrossRef
3.
go back to reference Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302–4.PubMedCrossRef Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302–4.PubMedCrossRef
4.
go back to reference Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol. 2009;131(2):168–79.PubMedCrossRef Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol. 2009;131(2):168–79.PubMedCrossRef
5.
go back to reference Fett JD, McTiernan CF. Towards a unifying hypothesis for the pathogenesis of peripartum cardiomyopathy. Int J Cardiol. 2011;153(1):1–3.PubMedCrossRef Fett JD, McTiernan CF. Towards a unifying hypothesis for the pathogenesis of peripartum cardiomyopathy. Int J Cardiol. 2011;153(1):1–3.PubMedCrossRef
6.
go back to reference Biteker M, Kayatas K, Duman D, Turkmen M, Bozkurt B. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev. 2014;10(4):317–26.PubMedPubMedCentralCrossRef Biteker M, Kayatas K, Duman D, Turkmen M, Bozkurt B. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev. 2014;10(4):317–26.PubMedPubMedCentralCrossRef
7.
go back to reference Dalzell JR, Jackson CE, Gardner RS. An update on peripartum cardiomyopathy. Expert Rev Cardiovasc Ther. 2011;9(9):1155–60.PubMedCrossRef Dalzell JR, Jackson CE, Gardner RS. An update on peripartum cardiomyopathy. Expert Rev Cardiovasc Ther. 2011;9(9):1155–60.PubMedCrossRef
8.
go back to reference Nishimoto O, Matsuda M, Nakamoto K, Nishiyama H, Kuraoka K, Taniyama K, Tamura R, Shimizu W, Kawamoto T. Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation. Intern Med. 2012;51(5):461–4.PubMedCrossRef Nishimoto O, Matsuda M, Nakamoto K, Nishiyama H, Kuraoka K, Taniyama K, Tamura R, Shimizu W, Kawamoto T. Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation. Intern Med. 2012;51(5):461–4.PubMedCrossRef
9.
go back to reference Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33–8.PubMedCrossRef Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33–8.PubMedCrossRef
10.
go back to reference Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012;14(8):895–901.PubMedCrossRef Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012;14(8):895–901.PubMedCrossRef
11.
go back to reference McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, et al. Clinical outcomes for Peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–14.PubMedPubMedCentralCrossRef McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, et al. Clinical outcomes for Peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–14.PubMedPubMedCentralCrossRef
12.
go back to reference Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LS, Illum S, Hatamizadeh P, Elkayam U. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15(8):645–50.PubMedCrossRef Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LS, Illum S, Hatamizadeh P, Elkayam U. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15(8):645–50.PubMedCrossRef
13.
go back to reference Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35(3):701–5.PubMedCrossRef Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35(3):701–5.PubMedCrossRef
14.
go back to reference Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80(12):1602–6.PubMedCrossRef Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80(12):1602–6.PubMedCrossRef
15.
go back to reference Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105(6):1303–8.PubMedCrossRef Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105(6):1303–8.PubMedCrossRef
16.
go back to reference Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, Sliwa K. Predictors of outcome in 176 south African patients with peripartum cardiomyopathy. Heart. 2013;99(5):308–13.PubMedCrossRef Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, Sliwa K. Predictors of outcome in 176 south African patients with peripartum cardiomyopathy. Heart. 2013;99(5):308–13.PubMedCrossRef
17.
go back to reference Libhaber E, Sliwa K, Bachelier K, Lamont K, Bohm M. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol. 2015;190:376–82.PubMedCrossRef Libhaber E, Sliwa K, Bachelier K, Lamont K, Bohm M. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol. 2015;190:376–82.PubMedCrossRef
18.
go back to reference Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.PubMedCrossRef Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.PubMedCrossRef
19.
go back to reference Sarojini A, Sai Ravi Shanker A, Anitha M. Inflammatory markers-serum level of C-reactive protein, tumor necrotic factor-alpha, and Interleukin-6 as predictors of outcome for Peripartum cardiomyopathy. J Obstet Gynaecol India. 2013;63(4):234–9.PubMedPubMedCentralCrossRef Sarojini A, Sai Ravi Shanker A, Anitha M. Inflammatory markers-serum level of C-reactive protein, tumor necrotic factor-alpha, and Interleukin-6 as predictors of outcome for Peripartum cardiomyopathy. J Obstet Gynaecol India. 2013;63(4):234–9.PubMedPubMedCentralCrossRef
20.
go back to reference Gleicher N, Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmun Rev. 2009;8(5):384–7.PubMedCrossRef Gleicher N, Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmun Rev. 2009;8(5):384–7.PubMedCrossRef
21.
go back to reference Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441–6.PubMedCrossRef Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441–6.PubMedCrossRef
22.
go back to reference Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988–98.CrossRefPubMed Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988–98.CrossRefPubMed
23.
go back to reference Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res. 2009;81(3):474–81.PubMedCrossRef Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res. 2009;81(3):474–81.PubMedCrossRef
25.
go back to reference Wrigley BJ, Shantsila E, Tapp LD, Lip GY. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Investig. 2013;43(2):121–30.CrossRef Wrigley BJ, Shantsila E, Tapp LD, Lip GY. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Investig. 2013;43(2):121–30.CrossRef
26.
go back to reference Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.PubMedPubMedCentralCrossRef Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.PubMedPubMedCentralCrossRef
27.
go back to reference Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689–93.PubMedPubMedCentralCrossRef Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689–93.PubMedPubMedCentralCrossRef
28.
go back to reference Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37(7):710–8.PubMedCrossRef Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37(7):710–8.PubMedCrossRef
29.
go back to reference Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr Med Chem. 2009;16(6):667–75.PubMedCrossRef Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr Med Chem. 2009;16(6):667–75.PubMedCrossRef
30.
go back to reference Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46(8):1619–25.PubMedCrossRef Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46(8):1619–25.PubMedCrossRef
31.
go back to reference Karatas MB, Canga Y, Ozcan KS, Ipek G, Gungor B, Onuk T, Durmus G, Oz A, Karaca M, Bolca O. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med. 2016;34(2):240–4.PubMedCrossRef Karatas MB, Canga Y, Ozcan KS, Ipek G, Gungor B, Onuk T, Durmus G, Oz A, Karaca M, Bolca O. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med. 2016;34(2):240–4.PubMedCrossRef
32.
go back to reference Yilmaz S, Akboga MK, Sen F, Balci KG, Aras D, Temizhan A, Aydogdu S. Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomark Med. 2016;10(9):959–66.PubMedCrossRef Yilmaz S, Akboga MK, Sen F, Balci KG, Aras D, Temizhan A, Aydogdu S. Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomark Med. 2016;10(9):959–66.PubMedCrossRef
33.
34.
go back to reference Kundi H, Gok M, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Karayigit O, Ornek E. Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. Am J Cardiol. 2015;116(11):1685–9.PubMedCrossRef Kundi H, Gok M, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Karayigit O, Ornek E. Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. Am J Cardiol. 2015;116(11):1685–9.PubMedCrossRef
35.
go back to reference Inonu Koseoglu H, Pazarli AC, Kanbay A, Demir O. Monocyte count/HDL cholesterol ratio and cardiovascular disease in patients with obstructive sleep apnea syndrome: a multicenter study. Clin Appl Thromb/Hemost. 2018;24(1):139–44.CrossRef Inonu Koseoglu H, Pazarli AC, Kanbay A, Demir O. Monocyte count/HDL cholesterol ratio and cardiovascular disease in patients with obstructive sleep apnea syndrome: a multicenter study. Clin Appl Thromb/Hemost. 2018;24(1):139–44.CrossRef
Metadata
Title
A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count- to- HDL cholesterol ratio
Authors
Firdevs Aysenur Ekizler
Serkan Cay
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Cardiomyopathy
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1100-9

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue